Table 1.
Characteristics of patients in relation to prescription of an anticoagulant.
| Factor | Prescribed Anticoagulant | p Value | |
|---|---|---|---|
| Yes | No | ||
| Number | 98 | 1063 | |
| Age (years) | 73.9 ± 7.6 | 73.0 ± 7.7 | 0.247 |
| Female | 17 (17.4%) | 188 (17.7%) | 0.933 |
| Smoking | 0.258 | ||
| Current | 22 (22.5%) | 282 (26.5%) | |
| Former | 67 (68.4%) | 640 (60.2%) | |
| Never | 9 (9.2%) | 141 (13.3%) | |
| Diabetes | 26 (26.5%) | 219 (20.6%) | 0.169 |
| Hypertension | 81 (82.7%) | 801 (75.4%) | 0.106 |
| Ischemic heart disease | 76 (77.6%) | 504 (47.4%) | <0.001 |
| Family history of aortic or peripheral aneurysm | 11 (11.2%) | 108 (10.2%) | 0.740 |
| Stroke | 15 (15.3%) | 101 (9.5%) | 0.067 |
| Aspirin | 32 (32.7%) | 649 (61.1%) | <0.001 |
| Other antiplatelet | 10 (10.2%) | 180 (16.9%) | 0.085 |
| Statin | 74 (75.5%) | 693 (65.2%) | 0.039 |
| Metformin | 12 (12.2%) | 127 (12.0%) | 0.931 |
| Frusemide prescribed for cardiac failure | 25 (25.5%) | 79 (7.4%) | <0.001 |
| Body mass index * | 28.2 ± 4.9 | 27.6 ± 5.0 | 0.251 |
| Initial AAA diameter | 44.2 ± 10.3 | 46.5 ± 11.4 | 0.053 |
| Follow-up (years) | 4.5 ± 4.3 | 4.9 ± 4.0 | 0.299 |
| AAA repair or AAA rupture related mortality | 32 (32.7%) | 504 (47.4%) | 0.005 |
| Major adverse cardiovascular events | 30 (30.6%) | 289 (27.2%) | 0.467 |
| Myocardial infarction | 10 (10.2%) | 109 (10.3%) | 0.988 |
| Stroke | 6 (6.1%) | 59 (5.6%) | 0.814 |
| Cardiovascular death | 22 (22.4%) | 202 (19.0%) | 0.408 |
| All-cause death | 42 (42.9%) | 394 (37.1%) | 0.257 |
Shown are number (percentage) or mean (±standard deviation). Missing from 123* patients. p values are from Chi-squared or two tailed independent t tests.